Severe Depression
16
2
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
Nebulized Ketamine for the Treatment of Major Depressive Disorder
REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group Intervention
At-Home tDCS as Maintenance Therapy
pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder
pBFS Guided 20min Inter-session Interval rTMS Treatment for MDD
The Dosage Effect of pBFS Guided rTMS Treatment for MDD
Improving Physical Health in Patients With Psychiatric Disorders in General Practice (SOFIA)
Probiotic Supplementation in Severe Depression
Community-based Mental Health Care for People With Severe and Enduring Mental III Health
Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy
Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
Community-based Mental Health Care for People With Severe and Enduring Mental III Health ( RECOVER-E )
Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health (RECOVER-E) Croatia
Psilocybin and Depression